Morning Buzz: Priceline (PCLN), Iconix Brand (ICON), Anavex (AVXL), Yahoo (YHOO), Edap (EDAP)

The Priceline Group Inc. (PCLN) shares are down $80.06, or 5.50%, to $1,369.84 in pre-market trading Monday despite the fact the company reported third-quarter earnings results that beat Wall Street estimates.

The online booking service posted earnings of $25.35 per share on revenues of $3.10 billion, up 9.4% from a year ago. Analysts were expecting EPS of $24.24 on revenues of $3.06 billion. For the current quarter ending in December, Priceline provided EPS guidance of $11.10 to $11.90 versus consensus of $12.39 per share. The company also issued revenue projection of $1.86 to $1.99 billion, compared to the consensus revenue estimate of $2.05 billion.

Iconix Brand Group, Inc. (ICON) reported third-quarter EPS of $0.33 before the opening bell Monday, compared to the consensus estimate of $0.21. Revenues decreased 19.4% from last year to $88.9 million. Analysts expected revenues of $89.06 million.

The clothing brand licensing company guided FY15 revenues of $370 – $380 million, as compared to analysts’ expectations of $375.95 million. The management also gave its bottom line range of $1.35 – $1.40 per share, against projections of $1.38 per share.

ICON is currently up $1.00 to $7.90 on 448K shares.

Shares of New, York-based Anavex Life Sciences Corp. (AVXL) have risen nearly 22% in pre-market trading Monday after announcing positive safety and cognitive efficacy data for ANAVEX 2-73, the company’s lead investigational oral treatment for Alzheimer’s disease. Study met the primary objective of safety.

Yahoo (YHOO) – Re/code reports that Yahoo has hired McKinsey & Co. to help with the reorganization of its core businesses. McKinsey will help the web portal to decide which units to shut, sell or invest in, the report said, citing several people close to the situation.

Shares of EDAP TMS SA (EDAP) are surging on Monday, up $1.26, or 22.95%, at $6.75. The name gained momentum after announcing that it has received 510(k) clearance from the FDA to market Ablatherm(R) Integrated Imaging HIFU in the U.S. for the ablation of prostate tissue. EDAP said it expects to commercialize Ablatherm(R) HIFU in the U.S. immediately.

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.